Stay updated on Pembrolizumab & Lenvatinib in Neuroendocrine Tumors Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab & Lenvatinib in Neuroendocrine Tumors Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab & Lenvatinib in Neuroendocrine Tumors Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T21:04:54.000Z thumbnail image
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a potential update in the study results or data related to the Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors, focusing on assessing overall radiographic response rate (ORR), progression-free survival (PFS), and the safety of the treatment combination.
    Difference
    0.1%
    Check dated 2024-06-06T14:25:20.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to specify that researchers look for people who fit certain eligibility criteria, such as general health condition or prior treatments. This change provides a more detailed description of the criteria used to determine eligibility for the study.
    Difference
    52%
    Check dated 2024-05-22T21:19:34.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    0.9%
    Check dated 2024-04-30T22:29:23.000Z thumbnail image

Stay in the know with updates to Pembrolizumab & Lenvatinib in Neuroendocrine Tumors Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Lenvatinib in Neuroendocrine Tumors Clinical Trial page.